Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Put a Drop of Timolol Into Each Eye and Call Me in the Morning

Put a Drop of Timolol Into Each Eye and Call Me in the Morning Research Original Investigation Short-term Efficacy and Safety of Topical β-Blockers in Acute Migraine 21. Janakiraman RK, Ramasamy C. Pre-clinical 22. Gilmore B, Michael M. Treatment of acute 23. Mayans L, Walling A. Acute migraine headache: studies of timolol maleate matrix tablet formulated migraine headache. Am Fam Physician. 2011;83(3): treatment strategies. Am Fam Physician. 2018;97 with different polymers and ratios. Asian J Res Biol 271-280. (4):243-251. Pharm Sci. 2014;2(1):38-55. Accessed August 24, 2020. https://docisolation.prod.fire.glass/?guid= 9df27275-4fc9-4187-7614-2855499af36a Invited Commentary Bradley J. Katz, MD, PhD Migraine is the most common, chronic, serious neurologic con- the drops and recorded their headaches in a diary. At the conclu- sion of the trial, the 50 patients had recorded a total of 619 dition worldwide, affecting more than 11% of the world’s population. In the United States, it affects approximately 16% migraine attacks. Just under half of the attacks were treated with of women and 6% of men. Although migraine is a neurologic timolol, and just under half of the attacks were treated with illness, it is associated with a the placebo. The authors report that 233 timolol-treated attacks number of ocular and visual (82%) were associated with a clinically significant reduction in Related article page 1160 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Ophthalmology American Medical Association

Put a Drop of Timolol Into Each Eye and Call Me in the Morning

JAMA Ophthalmology , Volume 138 (11) – Nov 1, 2020

Loading next page...
 
/lp/american-medical-association/put-a-drop-of-timolol-into-each-eye-and-call-me-in-the-morning-BAmPqjQFx6
Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2168-6165
eISSN
2168-6173
DOI
10.1001/jamaophthalmol.2020.3837
Publisher site
See Article on Publisher Site

Abstract

Research Original Investigation Short-term Efficacy and Safety of Topical β-Blockers in Acute Migraine 21. Janakiraman RK, Ramasamy C. Pre-clinical 22. Gilmore B, Michael M. Treatment of acute 23. Mayans L, Walling A. Acute migraine headache: studies of timolol maleate matrix tablet formulated migraine headache. Am Fam Physician. 2011;83(3): treatment strategies. Am Fam Physician. 2018;97 with different polymers and ratios. Asian J Res Biol 271-280. (4):243-251. Pharm Sci. 2014;2(1):38-55. Accessed August 24, 2020. https://docisolation.prod.fire.glass/?guid= 9df27275-4fc9-4187-7614-2855499af36a Invited Commentary Bradley J. Katz, MD, PhD Migraine is the most common, chronic, serious neurologic con- the drops and recorded their headaches in a diary. At the conclu- sion of the trial, the 50 patients had recorded a total of 619 dition worldwide, affecting more than 11% of the world’s population. In the United States, it affects approximately 16% migraine attacks. Just under half of the attacks were treated with of women and 6% of men. Although migraine is a neurologic timolol, and just under half of the attacks were treated with illness, it is associated with a the placebo. The authors report that 233 timolol-treated attacks number of ocular and visual (82%) were associated with a clinically significant reduction in Related article page 1160

Journal

JAMA OphthalmologyAmerican Medical Association

Published: Nov 1, 2020

References